Prospective assessment of levetiracetam pharmacokinetics during dose escalation in 4- to 12-year-old children with partial-onset seizures on concomitant carbamazepine or valproate

Epilepsy Research

Volumn 74, Issue 1, 2007, Pages 60-69

  Fountain, Nathan B ^a   Conry, Joan A ^b   Rodríguez Leyva, Ildefonso ^c   Gutierrez Moctezuma, Juvenal ^d   Salas, Edubijes ^e  

^a UNIVERSITY OF VIRGINIA   (United States)

^b CHILDREN'S NATIONAL MEDICAL CENTER   (United States)

^c Hospital Central   (Mexico)

^d Centro Medico Nacional 20 de Noviembre   (Mexico)

^e Sarah)   (Belgium)

Author keywords

Antiepileptic drugs; Children; Levetiracetam; Partial onset seizures; Pharmacokinetics

Indexed keywords

CARBAMAZEPINE; CARBOXYLIC ACID DERIVATIVE; DRUG METABOLITE; ETIRACETAM; UCB L057; UNCLASSIFIED DRUG; VALPROIC ACID;

ABDOMINAL PAIN; ALBUMINURIA; ANOREXIA; AREA UNDER THE CURVE; ARTICLE; CHILD; CLINICAL ARTICLE; CLINICAL TRIAL; CORRELATION ANALYSIS; COUGHING; DIZZINESS; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DOSE TITRATION; DRUG EFFECT; DRUG EFFICACY; DRUG HALF LIFE; DRUG RESPONSE; DRUG SAFETY; DRUG SALIVA LEVEL; FEMALE; FOCAL EPILEPSY; GLOBAL EVALUATION SCALE; HUMAN; LEUKOPENIA; MALE; MULTICENTER STUDY; OPEN STUDY; PHARYNGITIS; PRIORITY JOURNAL; PROSPECTIVE STUDY; RATING SCALE; SOMNOLENCE;

ANTICONVULSANTS; CARBAMAZEPINE; CHILD; CHILD, PRESCHOOL; DRUG THERAPY, COMBINATION; EPILEPSIES, PARTIAL; HUMANS; PIRACETAM; SALIVA; VALPROIC ACID;

EID: 33947244366     PISSN: 09201211     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.eplepsyres.2006.12.005     Document Type: Article

References (36)

1. Anderson G.D. A mechanistic approach to antiepileptic drug interactions. Ann. Pharmacother. 32 (1998) 554-563
2. Arroyo S., and Crawford P. Safety profile of levetiracetam. Epileptic Disord. 5 (2003) S57-S63
3. Ben-Menachem E., and Falter U. Efficacy and tolerability of levetiracetam 3000 mg/d in patients with refractory partial seizures: a multicenter, double-blind, responder-selected study evaluating monotherapy. European Levetiracetam Study Group. Epilepsia 41 (2000) 1276-1283
4. Bourgeois B.F. Antiepileptic drugs in pediatric practice. Epilepsia 36 (1995) S34-S45
5. Cereghino J.J., Biton V., Abou-Khalil B., Dreifuss F., Gauer L.J., and Leppik I. Levetiracetam for partial seizures: results of a double-blind, randomized clinical trial. Neurology 55 (2000) 236-242
6. Contin M., Albani F., Riva R., and Baruzzi A. Levetiracetam therapeutic monitoring in patients with epilepsy: effect of concomitant antiepileptic drugs. Ther. Drug Monit. 26 (2004) 375-379
7. Coppola G., Mangano S., Tortorella G., Pelliccia A., Fels A., Romano A., Nardello R., Habetswallner F., Licciardi F., Operto F.F., and Pascotto A. Levetiracetam during 1-year follow-up in children, adolescents, and young adults with refractory epilepsy. Epilepsy Res. 59 (2004) 35-42
8. Coupez R., Nicolas J.M., and Browne T.R. Levetiracetam, a new antiepileptic agent: lack of in vitro and in vivo pharmacokinetic interaction with valproic acid. Epilepsia 44 (2003) 171-178
9. Crowder K.M., Gunther J.M., Jones T.A., Hale B.D., Zhang H.Z., Peterson M.R., Scheller R.H., Chavkin C., and Bajjalieh S.M. Abnormal neurotransmission in mice lacking synaptic vesicle protein 2A (SV2A). PNAS 96 (1999) 15268-15273
10. Ethell B.T., Anderson G.D., and Burchell B. The effect of valproic acid on drug and steroid glucuronidation by expressed human UDP-glucuronosyltransferases. Biochem. Pharmacol. 65 (2003) 1441-1449
11. Fuks B., Gillard M., Michel P., Lynch B., Vertongen P., Leprince P., Klitgaard H., and Chatelain P. Localization and photoaffinity labelling of the levetiracetam binding site in rat brain and certain cell lines. Eur. J. Pharmacol. 478 (2003) 11-19
12. Gidal B.E., Baltes E., Otoul C., and Perucca E. Effect of levetiracetam on the pharmacokinetics of adjunctive antiepileptic drugs: a pooled analysis of data from randomized clinical trials. Epilepsy Res. 64 (2005) 1-11
13. Glauser T.A., Pellock J.M., Bebin E.M., Fountain N.B., Ritter F.J., Jensen C.M., and Shields W.D. Efficacy and safety of levetiracetam in children with partial seizures: an open-label trial. Epilepsia 43 (2002) 518-524
14. Glauser T.A., Ayala R., Elterman R.D., Mitchell W.G., Van Orman C.B., Gauer L.J., and Lu Z. Double-blind placebo-controlled trial of adjunctive levetiracetam in pediatric partial seizures. Neurology 66 (2006) 1654-1660
15. Gough K., Hutchison M., Keene O., Byrom B., Ellis S., Lacey L., and McKellar J. Assessment of dose proportionality: report from the statisticians in the pharmaceutical industry/pharmacokinetics UK joint working party. Drug Inf. J. 29 (1995) 1039-1048
16. Hauser W.A. Seizure disorders: the changes with age. Epilepsia 33 Suppl. 4 (1992) S6-S14
17. Hauser W.A. The prevalence and incidence of convulsive disorders in children. Epilepsia 35 (1994) S1-S6
18. ILAE. Proposal for revised clinical and electroencephalographic classification of epileptic seizures. From the Commission on Classification and Terminology of the International League Against Epilepsy. Epilepsia 22 (1981) 489-501
19. Lagae L., Buyse G., Deconinck A., and Ceulemans B. Effect of levetiracetam in refractory childhood epilepsy syndromes. Eur. J. Paediatr. Neurol. 7 (2003) 123-128
20. Lagae L., Buyse G., and Ceulemans B. Clinical experience with levetiracetam in childhood epilepsy: an add-on and mono-therapy trial. Seizure 14 (2005) 66-71
21. Lins R.L., Otoul C., De Smedt F., Coupez R., and Stockis A. Drug monitoring: comparison of plasma and saliva concentrations of levetiracetam administered as tablet or solution in healthy adult volunteers. Int. J. Clin. Pharmacol. Ther. 45 (2007) 47-54
22. Lynch B.A., Lambeng N., Nocka K., Kensel-Hammes P., Bajjalieh S.M., Matagne A., and Fuks B. The synaptic vesicle protein SV2A is the binding site for the antiepileptic drug levetiracetam. Proc. Natl. Acad. Sci. U.S.A. 101 (2004) 9861-9866
23. May T.W., Rambeck B., and Jurgens U. Serum concentrations of Levetiracetam in epileptic patients: the influence of dose and co-medication. Ther. Drug Monit. 25 (2003) 690-699
24. Nicolas J.M., Collart P., Gerin B., Mather G., Trager W., Levy R., and Roba J. In vitro evaluation of potential drug interactions with levetiracetam, a new antiepileptic agent. Drug Metab. Dispos. 27 (1999) 250-254
25. Noyer M., Gillard M., Matagne A., Henichart J.P., and Wulfert E. The novel antiepileptic drug levetiracetam (ucb L059) appears to act via a specific binding site in CNS membranes. Eur. J. Pharmacol. 286 (1995) 137-146
26. Otoul C., Arrigo C., van Rijckevorsel K., and French J.A. Meta-analysis and indirect comparisons of levetiracetam with other second-generation antiepileptic drugs in partial epilepsy. Clin. Neuropharmacol. 28 (2005) 72-78
27. Patsalos P.N. Pharmacokinetic profile of levetiracetam: toward ideal characteristics. Pharmacol. Ther. 85 (2000) 77-85
28. Patsalos P.N. Clinical pharmacokinetics of levetiracetam. Clin. Pharmacokinet. 43 (2004) 707-724
29. Pellock J.M. Managing pediatric epilepsy syndromes with new antiepileptic drugs. Pediatrics 104 (1999) 1106-1116
30. Pellock J.M., Glauser T.A., Bebin E.M., Fountain N.B., Ritter F.J., Coupez R.M., and Shields W.D. Pharmacokinetic study of levetiracetam in children. Epilepsia 42 (2001) 1574-1579
31. Perucca E., Gidal B.E., and Baltes E. Effects of antiepileptic comedication on levetiracetam pharmacokinetics: a pooled analysis of data from randomized adjunctive therapy trials. Epilepsy Res. 53 (2003) 47-56
32. Shorvon S.D., Lowenthal A., Janz D., Bielen E., and Loiseau P. Multicenter double-blind, randomized, placebo-controlled trial of levetiracetam as add-on therapy in patients with refractory partial seizures. European Levetiracetam Study Group. Epilepsia 41 (2000) 1179-1186
33. Tan M.J., and Appleton R.E. Efficacy and tolerability of levetiracetam in children aged 10 years and younger: a clinical experience. Seizure 13 (2004) 142-145
34. Trinka E., Unterrainer J., Unterberger I., Luef G., Deisenhammer F., and Bauer G. One-year postmarketing experience with levetiracetam for treatment of drug-resistant epilepsy: a cross-sectional study [abstract 2.215]. Epilepsia 43 (2002) 202
35. Welty T.E., Gidal B.E., Ficker D.M., and Privitera M.D. Levetiracetam: a different approach to the pharmacotherapy of epilepsy. Ann. Pharmacother. 36 (2002) 296-304
36. Wheless J.W., and Ng Y.T. Levetiracetam in refractory pediatric epilepsy. J. Child Neurol. 17 (2002) 413-415